{"title":"Immunocore’s ImmTAC ® Platform Gains Big Pharma Recognition with Genentech Pact","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I7.1967","DOIUrl":null,"url":null,"abstract":"Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I7.1967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
